

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 21<sup>st</sup> September, 2017

To,  
Bombay Stock Exchange Ltd.  
Department of Corporate Services.  
25<sup>th</sup> Floor, P.J.Towers, Dalal Street,  
Mumbai-400 001

Script ID: 506365

SUBJECT: SUBMISSION OF REVISED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2017

Dear Sir,


With reference to letter received from Exchange in regard to Non-Compliance of Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to submit the Revised Financial Results along with Limited Review Report and Reconciliation of Profit and Loss for the quarter ended 30<sup>th</sup> June, 2017 as per the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.

You are requested to take the same into consideration.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI

DIRECTOR

(DIN NO. - 03063364)





**LIMITED REVIEW REPORT**

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30<sup>th</sup> June, 2017**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

NO: C/05/0717  
Dated: 18/07/2017  
Place: MUMBAI



For M/s VMD & CO.  
Chartered Accountants.  
FRN: 12502W

  
CA AMIT GANPULE  
PARTNER  
MRN: 114222

# CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2017

Sr. No.	Particulars	(Rupees in Thousand)			
		Quarter Ended		Year Ended	
		30th June 2017	31st March 2017	30th June 2016	31st March 2017
		Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-
II	Other Income	-	-	-	-
III	<b>Total Revenue (I + II)</b>	<b>1,377</b>	<b>53,114</b>	<b>924</b>	<b>56,080</b>
IV	<b>Expenses</b>	<b>1,377</b>	<b>53,114</b>	<b>924</b>	<b>56,080</b>
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	244	234	191	805
	(5) Depreciation and Amortisation Expenses	-	-	-	-
	(6) Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown seperately)	165	471	36	872
	i) Professional Charges	67	409	20	699
	ii) Share Registry Expenses	15	26	14	92
	iii) Annual Listing Fees	298	-	256	-
	(7) Finance Costs	-	-	-	-
	<b>Total Expenses</b>	<b>789</b>	<b>1,140</b>	<b>517</b>	<b>2,724</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>588</b>	<b>51,975</b>	<b>407</b>	<b>53,356</b>
VI	Exceptional Items	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>588</b>	<b>51,975</b>	<b>407</b>	<b>53,356</b>
VIII	Extra Ordinary Items	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>588</b>	<b>51,975</b>	<b>407</b>	<b>53,356</b>
X	Tax Expenses	-	-	-	-
	(1) Current Tax	5,177	6,515	-	6,515
	(2) Deffered Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	(4,589)	45,460	407	46,841
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>(4,589)</b>	<b>45,460</b>	<b>407</b>	<b>46,841</b>
XVI	Other Comprehensive Income				
	A (i) Itmes that will not be reclassified to profit or loss				
	(ii) Income rax relating to items that will not be reclassified to profit or loss				
	B (i) Itmes that will not be reclassified to profit or loss				
	(ii) Income rax relating to items that will not be reclassified to profit or loss				
XVII	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Incoe for the period</b>	<b>(4,589.00)</b>	<b>45,459.50</b>	<b>407.00</b>	<b>46,841.00</b>
XVIII	<b>Earnings per Share :</b>				
	(1) Basic	(3.06)	30.31	0.27	31.23
	(2) Diluted				



# CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

EMAIL ID: [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)

## Notes :

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- 2 The above Un-Audited Financial Results for the Quarter Ended 30.06.2017 have been reviewed by the Audit Committee in their Meeting held on 18.07.2017 and approved by the Board of Directors of its Meeting held on 18.07.2017. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai  
Date : 18th July, 2017



For Chemo - Pharma Laboratories Limited

Ashok Somani  
Director

# CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301  
• CORPORATE OFFICE- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001  
• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294  
• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K  
WEBSITE: www.thechemopharmalaboratoriesltd.com  
EMAIL ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2017

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 30.06.2017	AUDITED YEAR ENDED 31.03.2017
<b>Reconciliation of Profit After Tax as reported earlier:</b>		
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>588.00</b>	<b>53,356.00</b>
<b>Benefit / (Charge):</b>		
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>588.00</b>	<b>53,356.00</b>

For Chemo Pharma Laboratories Ltd.



*Ashok Somani*

Ashok Somani  
Director

Date: 18th July, 2017

Place: Mumbai